Navigation Links
Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
Date:2/21/2008

GOTHENBURG, Sweden, February 21 /PRNewswire/ -- With two successful international product launches, Swedish biotech firm Cellectricon is entering a new expansion phase. The share issue will strengthen Cellectricon's financial capacity prior to a number of significant product launches in 2008-2009. These products have been developed in close collaboration with leading global pharmaceutical companies to meet the industry's increasing demand for fully automated, highly efficient systems for pre-clinical pharmaceutical development.

"Cellectricon is now entering a new expansion phase, in which the company will soon launch two large-scale systems that will revolutionize drug discovery. This capital will enable us to continue our rapid expansion in the United States, Europe, and Asia," said Dr. Mattias Karlsson, Cellectricon's CEO.

In 2008 Cellectricon will launch the first of their large-scale screening system, Cellaxess(R)HT, which has been developed in close cooperation with one of the world's largest pharmaceutical companies. Cellaxess(R)HT will be the only system on the market that enables large-scale supply of genetic material for cells and is tailor made for high throughput RNAi screening.

About Cellectricon

Cellectricon AB is a Swedish biotech company that is a successful provider of groundbreaking products to the pharmaceutical industry that increase efficiency in pre-clinical pharmaceutical development. Cellectricon has already successfully launched two products onto the market that have been sold to ten of the 12 largest pharmaceutical companies in the world. In 2007 the company increased its revenue by almost 50%. In 2008-2009 launch the high-performance systems Cellaxess(R)HT for RNAi screening and Dynaflow(R)HT for ion channel screening. Cellectricon's forthcoming products address a market that is estimated to be US $1.4 billion by 2010.


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. CardioDynamics Provides 2007 Shareholder Meeting Update
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
8. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Neuralstem Shares Accepted for Trading on Amex(R)
10. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
11. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):